Mineralys Therapeutics Announces Presentation of New Lorundrostat Data at the American Society of Nephrology (ASN) Kidney Week 2026

Impact · against what's priced in

Mineralys Therapeutics shares face a binary catalyst event as the company prepares to present Phase 3 Launch-HTN data for lorundrostat at ASN Kidney Week 2026. The market now has a concrete date (October 21-25) for the primary endpoint results regarding systolic blood pressure reduction in uncontrolled hypertension patients.

MLYS+0.60

No priced-in read yet